As of 2025-06-22, the Intrinsic Value of Alnylam Pharmaceuticals Inc (ALNY) is (132.15) USD. This Alnylam valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 309.70 USD, the upside of Alnylam Pharmaceuticals Inc is -142.70%.
The range of the Intrinsic Value is (256.56) - (90.49) USD
Based on its market price of 309.70 USD and our intrinsic valuation, Alnylam Pharmaceuticals Inc (ALNY) is overvalued by 142.70%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (256.56) - (90.49) | (132.15) | -142.7% |
| DCF (Growth 10y) | (137.79) - (382.20) | (199.43) | -164.4% |
| DCF (EBITDA 5y) | (24.35) - (26.92) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (47.25) - (51.63) | (1,234.50) | -123450.0% |
| Fair Value | -28.56 - -28.56 | -28.56 | -109.22% |
| P/E | (21.51) - (20.31) | (19.86) | -106.4% |
| EV/EBITDA | (2.83) - (3.55) | (3.04) | -101.0% |
| EPV | (35.63) - (46.64) | (41.13) | -113.3% |
| DDM - Stable | (22.77) - (88.14) | (55.45) | -117.9% |
| DDM - Multi | (80.12) - (243.65) | (120.90) | -139.0% |
| Market Cap (mil) | 40,381.78 |
| Beta | 1.17 |
| Outstanding shares (mil) | 130.39 |
| Enterprise Value (mil) | 40,387.69 |
| Market risk premium | 4.60% |
| Cost of Equity | 8.24% |
| Cost of Debt | 7.17% |
| WACC | 8.21% |